NDA 210660 · Exela Pharma
Elcys
Cysteine Hydrochloride · Intravenous
Priority reviewLast checked: Nov 20, 2026Latest source record: Dec 4, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Apr 16, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
600
111 Phase 3, 40 recruiting
FAERS reports
25
24 serious, 1 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Apr 9, 2026.
ELCYS ® is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN); and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. It can also be added to amino acid solutions to provide a more complete profile of amino acids for protein synthesis. ELCYS ® is a sulfur-containing amino acid indicated to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN); and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. It can also be added to amino acid solutions to provide a more complete profile of amino acids for protein synthesis. ( 1 )
Mechanism: Endogenous cysteine is synthesized from methionine by the enzyme, cystathionase, via the trans-sulfuration pathway, and serves as a precursor substrate for both glutathione and taurine. ELCYS ® provides cysteine to the systemic circulation of patients who require PN and cannot synthesize adequate quantities of cysteine due to insufficient or deficient cystathionase activity.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Apr 16, 2019 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
2 products under this application
- ELCYS · CYSTEINE HYDROCHLORIDE 500MG/10ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- ELCYS · CYSTEINE HYDROCHLORIDE 2500MG/50ML (50MG/ML) · SOLUTION, INTRAVENOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Cysteine" as an intervention, any sponsor and status, largest first.
- Therapeutics for Moderate and Severe DenguePivotal-lookingNot yet recruiting
Oxford University Clinical Research Unit, VietnamAcademic, hospital or other
NCT07543458 · 8,800 participants (planned) · Start Oct 1, 2026 · Primary completion Jul 31, 2030
Drug: Placebo; Dexamethasone and 2 more · For: Dengue; Severe Dengue; Mosquito-Borne Diseases and 5 more
Sites: Chittagong, Bangladesh; Dhaka, Bangladesh; São Paulo, Brazil · 18 sites in all
- ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 StudyPivotal-lookingStatus unknown
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT04609111 · 6,002 participants · Start Jan 29, 2021 · Primary completion Dec 31, 2023
Drug: No aspirin; 1-month DAPT · For: Acute Coronary Syndrome
Sites: Kyoto, Japan
- Prevention of Serious Adverse Events Following AngiographyPivotal-lookingCompleted
VA Office of Research and DevelopmentFederal agency
NCT01467466 · 5,177 participants · Start Oct 7, 2013 · Primary completion Sep 29, 2017
Drug: IV isotonic saline; IV isotonic bicarbonate and 2 more · For: Acute Renal Failure; Kidney Disease; Coronary Artery Disease
Sites: Tucson, Arizona; Little Rock, Arkansas; Palo Alto, California · 54 sites in all
- Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome PatientsPivotal-lookingStatus unknown
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Academic, hospital or other
NCT05125276 · 3,090 participants (planned) · Start May 13, 2022 · Primary completion Jul 2025
Drug: No aspirin; Aspirin · For: Non ST Segment Elevation Acute Coronary Syndrome
Sites: Amsterdam, Netherlands · 2 sites in all
- Efficacy and Safety of Aspirin in Patients With Chronic Coronary Syndromes Without RevascularizationPivotal-lookingRecruiting
Takeshi MorimotoAcademic, hospital or other
NCT05347069 · 2,890 participants (planned) · Start Jun 14, 2022 · Primary completion Mar 2030
Drug: Aspirin; No aspirin · For: Stable Angina Pectoris; Coronary Artery Disease; Ischemic Heart Disease
Sites: Kyoto, Japan
- Safety and Efficacy of Mucinex and IR Guaifenesin the Treatment of Symptoms of Acute Upper Respiratory Tract InfectionsPivotal-lookingCompleted
Reckitt Benckiser LLCIndustry
NCT01537081 · 2,810 participants · Start Sep 2011 · Primary completion Mar 2012
Drug: Mucinex; Immediate-release Guaifenesin and 1 more · For: Acute Upper Respiratory Tract Infection
Sites: Hoover, Alabama; Bell Gardens, California; Harbor City, California · 43 sites in all
- Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) TrialPivotal-lookingCompleted
Kumamoto UniversityAcademic, hospital or other
NCT00110448 · 2,539 participants · Start Dec 2002 · Primary completion Apr 2008
Drug: Aspirin; No aspirin · For: Coronary Disease; Arteriosclerosis; Diabetes Mellitus, Type 2
Sites: Kumamoto, Japan; Kashihara, Japan
- The Acetylcysteine for Contrast-Induced Nephropathy TrialPivotal-lookingCompleted
Hospital do CoracaoAcademic, hospital or other
NCT00736866 · 2,300 participants (planned) · Start Aug 2008 · Primary completion Jul 2010
Drug: Acetylcysteine; Placebo · For: Acute Kidney Failure
Sites: São Paulo, Brazil
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- hallucination6
- pneumonia4
- erythema multiforme3
- malaise3
- food craving2
- intentional product use issue2
- thirst2
- accidental exposure1
- altered state of consciousness1
- apnoea1
- atrial fibrillation1
- body temperature decreased1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2010 | 1 |
| 2012 | 7 |
| 2013 | 1 |
| 2016 | 1 |
| 2017 | 3 |
| 2018 | 2 |
| 2020 | 1 |
| 2021 | 3 |
| 2023 | 2 |
| 2026 | 1 |
Recalls
1 FDA enforcement reports for this application.
Oct 18, 2023 · Class I · Ongoing
Presence of Particulate Matter: Silicone
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Exercise training mode effects on myokine expression in healthy adults: A systematic review with meta-analysis.
Bettariga F, Taaffe DR, Galvão DA, et al. · J Sport Health Sci 2024 · Systematic Review, Meta-Analysis
- Antihypertensive Effects of an Optimized Aged Garlic Extract in Subjects with Grade I Hypertension and Antihypertensive Drug Therapy: A Randomized, Triple-Blind Controlled Trial.
Serrano JCE, Castro-Boqué E, García-Carrasco A, et al. · Nutrients 2023 · Randomized Controlled Trial
- Efficacy and tolerability of an oral supplement containing amino acids, iron, selenium, and marine hydrolyzed collagen in subjects with hair loss (androgenetic alopecia, AGA or FAGA or telogen effluvium). A prospective, randomized, 3-month, controlled, assessor-blinded study.
Milani M, Colombo F · Skin Res Technol 2023 · Randomized Controlled Trial
- Comparison of two-bag and three-bag acetylcysteine regimens in the treatment of paracetamol poisoning: a systematic review and meta-analysis.
Nakatsu L, Lopez JR, Garcia CM, et al. · Clin Toxicol (Phila) 2025 · Systematic Review, Meta-Analysis
- Differential alkylation-based redox proteomics--Lessons learnt.
Wojdyla K, Rogowska-Wrzesinska A · Redox Biol 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- A prospective randomized controlled trial of antioxidants in human IVF and embryo culture media.
Kelley RL, Lee YSL, Agresta F, et al. · Hum Reprod 2025 · Equivalence Trial, Randomized Controlled Trial
Sponsor: Exela Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.